Reapplix A/S
http://www.reapplix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reapplix A/S
Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement
Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
Reapplix Eyes US Market With Trial Results For Wound-Healing Tech
Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.
Reapplix Seals In More Funding For Diabetic Foot Ulcer Patch
Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.
Company Information
- Industry
- Medical Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice